Trial · NCT05334485
Pyridostigmine Efficacy and Safety for Treatment of Ileus After Colorectal Surgery
NCT05334485, Phase 2, Phase 3, Recruiting, Stefan Holubar MD MS FACS, FASCRS
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pyridostigmine Efficacy and Safety for Treatment of Ileus After Colorectal Surgery. Trials, record NCT05334485. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05334485
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pyridostigmine Efficacy and Safety for Treatment of Ileus After Colorectal Surgery
- NCT number
- NCT05334485
- Status
- Recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Stefan Holubar MD MS FACS, FASCRS
- Conditions
- Postoperative Ileus
- Interventions
- Pyridostigmine Bromide, Placebo
- First posted
- 2022-04-19
- Last updated
- 2026-01-07
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time until return of bowel function | Time from administration of pyridostigmine bromide or placebo until first passage of flatus for up to 30 days | Following the administration of either pyridostigmine bromide or placebo, the time (in minutes) until return of bowel function will be recorded. Return of bowel function is defined as the first passage of flatus. |
| Primary | Incidence of pyridostigmine bromide associated side effects | Participants will complete the survey at enrollment and then again at 30 minutes following each administration of either pyridostigmine bromide or placebo. | Side effects of pyridostigmine bromide will be assessed using the Pyridostigmine Bromide Side Effects Scale (PBSES) survey tool. Participants will complete this survey at specific time points to evaluate and monitor for the development of established side effects associated with pyridostigmine bromide administration. |
| Secondary | Time to passage of stool after postoperative ileus diagnosis | Time from the point of postoperative ileus diagnosis until the first passage of stool for up to 30 days | The amount of time (in minutes) from the participant being diagnosed with postoperative ileus confirmed with imaging findings until the first passage of stool. |
| Secondary | Time to tolerance of solid food after postoperative ileus | Time from the point of postoperative ileus diagnosis until first meal in which solid food is tolerated for up to 30 days | The amount of time (in minutes) from the participant being diagnosed with postoperative ileus confirmed with imaging findings until the first tolerance of solid food. |
| Secondary | Number of participants with complications | 30-day period following surgery | The number of participants with any type of complication or adverse event occurring within the first 30-days following surgery. |
| Secondary | Number of participants requiring re-operation | 30-day period following initial surgery | The number of participants who require a re-operation for any reason during the first 30-days following the initial operation. |
| Secondary | Number of participants requiring re-admission | 30-day period following surgery | The number of participants requiring re-admission to the hospital for any reason during the first 30-days following surgery. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05334485
GET https://conductscience.org/api/trials/v1/NCT05334485/registered